The MoBot Report

October 25, 2024

DENVER, Colo., Oct 25, 2024 (247marketnews.com)- MoBot’s recent alerts involved , Upexi (NASDAQ: UPXI), Iterum (NASDAQ: ITRM), ImmunityBio (NASDAQ: IBRX), Bright Minds (NASDAQ: DRUG), and Nexalin (NASDAQ: NXL).

MoBot posted Upexi (NASDAQ: UPXI) MoBot posted Upexi (NASDAQ:UPXI) yesterday at $5.597 and $UPXI is following through today, hitting a high of $15.91.

This morning, Upexi (NASDAQ: UPXI) stated that it’s taking action concerning its recently completed reverse stock split, as 5 brokerage firms requested roundup shares equaling over 199,000 shares of the Company’s common stock, out of a total of 202,183 round up shares of the Company’s common stock requested.

The 202,183 requested roundup shares is approximately 19% of the Company’s outstanding shares of common stock post-split and represents an increase of approximately 40 times the number of individual shareholders owning the Company’s common stock.

Allan Marshall, Upexi’s CEO, stated, “The Company intends to pursue this issue to the fullest extent necessary to protect the Company’s shareholders exposed to the issue and to help other listed companies to avoid this issue going forward.”

MoBot alerted Iterum (NASDAQ: ITRM) this morning at $1.312 and $ITRM topped out at $2.32.

Iterum (NASDAQ: ITRM) reported that the FDA approved its new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options, which is a first for ORLYNVAH and Iterum.

ImmunityBio (NASDAQ: IBRX) caught MoBot’s scanner yesterday at $3.813. IBRX is trading over $6 and looks like it still has legs.

ImmunityBio (NASDAQ: IBRX) reported dosing the first patients in an initial trial studying the potential of “the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are being tested initially as a single agent, and after demonstrating safety, then in combination with standard NHL treatment rituximab, in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants and is being conducted in Johannesburg, Pretoria, and Bloemfontein, South Africa.”

Bright Minds (NASDAQ: DRUG), which MoBot alerted at $1.426, on Oct 14, before it ran to a new 52-week high of $79.02, continues to trade around the $50 level.

Bright Minds (NASDAQ: DRUG) stated, on Monday, that it is again collaborating with Firefly Neuroscience (NASDAQ: AIFF) to thoroughly evaluate the electroencephalogram (EEG) data in Bright Minds’ BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Nexalin (NASDAQ: NXL) caught MoBot’s attention last week at $1.03 and multiple times since, including today’s first alert at $1.756 and less than 30 minutes later, it eclipsed $$2.45.

Wednesday, Nexalin stated that it plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD) and that Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation with the San Diego VA to recruit some of the patients for the study who have been victims of Traumatic Brain Injury (TBI). This trial will focus on the effectiveness of Nexalin’s Gen-3 Halo headset, designed to be used in a virtual clinic model, allowing patients to receive treatment from the convenience and privacy of their own home thus overriding the inconvenience and stigma of visiting a psychiatry office or VA Hospital.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (UPXI, ITRM, IBRX, DRUG, NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.